The online version of this article (doi:10.1186/1476-4598-11-2) contains supplementary material, which is available to authorized users.
Aaron M Marshall, Rebecca J McClaine contributed equally to this work.
The authors declare that they have no competing interests.
AMM and RJM were involved in the design, acquisition and analysis of the data as well as in drafting the manuscript. JKG, DG and KEL were involved in the acquisition of data. SAK was involved in the conception of the studies and the design of reagents for the ERα mouse model. SEW was involved in the conception and design of the study as well as in drafting and revising the manuscript. All authors have read and have approved the final manuscript.
The receptor tyrosine kinase family includes many transmembrane proteins with diverse physiological and pathophysiological functions. The involvement of tyrosine kinase signaling in promoting a more aggressive tumor phenotype within the context of chemotherapeutic evasion is gaining recognition. The Ron receptor is a tyrosine kinase receptor that has been implicated in the progression of breast cancer and evasion of tamoxifen therapy.
Here, we report that Ron expression is correlated with in situ, estrogen receptor alpha (ERα)-positive tumors, and is higher in breast tumors following neoadjuvant tamoxifen therapy. We also demonstrate that the majority of mammary tumors isolated from transgenic mice with mammary specific-Ron overexpression (MMTV-Ron mice), exhibit appreciable ER expression. Moreover, genetic-ablation of ERα, in the context of Ron overexpression, leads to delayed mammary tumor initiation and growth, but also results in an increased metastasis.
Ron receptor overexpression is associated with ERα-positive human and murine breast tumors. In addition, loss of ERα on a Ron overexpressing background in mice leads to the development of breast tumors which grow slower but which exhibit more metastasis and suggests that targeting of ERα, as in the case of tamoxifen therapy, may reduce the growth of Ron overexpressing breast cancers but may cause these tumors to be more metastatic.
Authors’ original file for figure 112943_2011_984_MOESM1_ESM.tiff
Authors’ original file for figure 212943_2011_984_MOESM2_ESM.tiff
Authors’ original file for figure 312943_2011_984_MOESM3_ESM.tiff
Authors’ original file for figure 412943_2011_984_MOESM4_ESM.tiff
Authors’ original file for figure 512943_2011_984_MOESM5_ESM.tiff
Authors’ original file for figure 612943_2011_984_MOESM6_ESM.tiff
Authors’ original file for figure 712943_2011_984_MOESM7_ESM.tiff
Clarke R, Leonessa F, Welch JN, Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev. 2001, 53: 25-71. PubMed
Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE: Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 2006, 66: 11967-11974. 10.1158/0008-5472.CAN-06-2473 CrossRefPubMed
Daniel CW, Silberstein GB, Strickland P: Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res. 1987, 47: 6052-6057. PubMed
Silberstein GB, Van Horn K, Shyamala G, Daniel CW: Essential role of endogenous estrogen in directly stimulating mammary growth demonstrated by implants containing pure antiestrogens. Endocrinology. 1994, 134: 84-90. 10.1210/en.134.1.84 PubMed
Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP, Waltz SE: beta-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene. 2011,
Augereau P, Miralles F, Cavailles V, Gaudelet C, Parker M, Rochefort H: Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol. 1994, 8: 693-703. 10.1210/me.8.6.693 PubMed
Liu QP, Fruit K, Ward J, Correll PH: Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol. 1999, 163: 6606-6613. PubMed
Nikolaidis NM, Gray JK, Gurusamy D, Fox W, Stuart WD, Huber N, Waltz SE: Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock. 2010, 33: 197-204. 10.1097/SHK.0b013e3181ae8155 PubMedCentralCrossRefPubMed
de la Haba J, Gomez A, Duenas R, Ribelles N, Mendez MJ, Serrano R, Font P, Aranda E: The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse. Eur J Surg Oncol. 2004, 30: 346-351. 10.1016/j.ejso.2003.10.006 CrossRefPubMed
- Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice
Aaron M Marshall
Rebecca J McClaine
Jerilyn K Gray
Kara E Lewnard
Sohaib A Khan
Susan E Waltz
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II